Abstract

Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, et al. Onco Targets Ther. 2018;11:8823–8833.

The authors have advised that an error during the preparation of the slide images for Figure 2C, on page 8827, led to the inadvertent duplication of features on the HV slide. All the original data was retained and the correct image for the HV treated chamber was used as a replacement. The correct Figure 2 is shown in Download Article.

Details

Title
Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]
Author
Pérez-Cárdenas, E  VIAFID ORCID Logo  ; Taja-Chayeb, L  VIAFID ORCID Logo  ; Trejo-Becerril, C; Chanona-Vilchis, J; Chávez-Blanco, A  VIAFID ORCID Logo  ; Domínguez-Gómez, G; Langley, E  VIAFID ORCID Logo  ; García-Carrancá, A  VIAFID ORCID Logo  ; Dueñas-González, A
Pages
845-846
Section
Corrigendum
Publication year
2022
Publication date
2022
Publisher
Taylor & Francis Ltd.
e-ISSN
1178-6930
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.2147/OTT.S382501
ProQuest document ID
2703154022
Copyright
© 2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.